On February 13, 2023, the U.S. Drug Enforcement Administration (DEA) issued a regulatory opinion on the control status of tetrahydrocannabinol acetate ester (THCO), confirming that the agency classifies delta-8-THCO and delta-9-THCO as schedule 1 controlled substances.